Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?

Weijst, Lotte van der; Surmont, Veerle; Schrauwen, Wim; Lievens, Yolande

doi:10.1016/j.critrevonc.2017.09.014

Cited by 15 publications

(18 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, more recently, researchers' reporting on how they handled missing data seems to have improved; a systematic review in 2017 found that only 5% of investigators failed to report the statistical methods they used to deal with missing data. 93 Gaps in data collection cannot only lead to biased research findings but can also diminish power to detect differences, and create barriers to applying standard statistical methodology. 94 For instance, Quinten and colleagues found a significant association between baseline PRO compliance and WHO performance status, distant metastases, and cancer site, 21 suggesting that patients in the noncompliance group or the missing group could be disproportionately sicker than those who completed the PRO data.…”

Section: Reducing Missing Datamentioning

confidence: 99%

“…The issue of missing data is more prominent in longitudinal lung cancer trials, given multiple factors that could affect compliance, such as survival rates and institutional errors. 18,93 Thus, investigators should recognize the importance of developing strategies for both minimizing and coping with missing data in lung cancer clinical trials.…”

Section: Reducing Missing Datamentioning

confidence: 99%

“…First, during the study-design phase, researchers should anticipate the potential for missing data and attrition when calculating sample size, to ensure that enough power is achieved despite a certain type of missing data. 93 Second, also during the design phase, they should plan how they will handle missing data. Third, during the data collection phase, the research team and study participants should be informed of the importance of collecting PRO data in clinical trials.…”

Section: Reducing Missing Datamentioning

confidence: 99%

“…10 By 2017, this number had increased, but 37% of studies still did not describe PRO hypotheses. 93 This is critical because describing a hypothesis for the primary endpoint is necessary for power calculation and statistical design for studies of PRO measurements. Furthermore, the majority of studies measured changes in PRO scores over time by calculating mean group differences at discrete time points.…”

Section: Hypothesis and Statistical Modelsmentioning

confidence: 99%

“…Furthermore, the majority of studies measured changes in PRO scores over time by calculating mean group differences at discrete time points. 93 Although this method provides direct comparisons between arms at each time point, it has a few weaknesses, such as ignoring sampling hierarchy differences among different locations in multisite clinical trials; assuming independence of observation in repeated measures; and not being able to handle missing data. 97,98 Mixedeffect modeling has been recommended for longitudinal studies with repeated PRO measures, because this method can overcome the above-described weaknesses from mean difference comparison at each time point.…”

Section: Hypothesis and Statistical Modelsmentioning

confidence: 99%

See 4 more Smart Citations

The State of the Science in Patient-Reported Outcomes for Patients with Lung Cancer

Xiao

Hurst

Movsas

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Traditionally, clinicians have assumed the primary responsibility for evaluating disease- and treatment-related outcomes. In the past few decades, however, a series of recommendations and standards promulgated by professional societies and regulatory agencies have resulted in increased use of patient-reported outcome (PRO) measures in cancer clinical trials. PROs, such as quality of life (QOL) measures, are important in establishing overall treatment effectiveness in cancer clinical trials, and they can inform clinical decision making. This article discusses the current state of the science in PRO research for patients with lung cancer, the cancer type with the highest incidence rate and the lowest survival rate worldwide. The discussion focuses on (1) PRO and survival; (2) electronic PRO reporting and interventions; (3) PROs and immunotherapy; (4) PRO, biomarkers, and precision health; (5) key issues in applying PROs in clinical trials; and (6) future directions for research.

show abstract

Section: Reducing Missing Datamentioning

confidence: 99%

Section: Reducing Missing Datamentioning

confidence: 99%

Section: Reducing Missing Datamentioning

confidence: 99%

Section: Hypothesis and Statistical Modelsmentioning

confidence: 99%

Section: Hypothesis and Statistical Modelsmentioning

confidence: 99%

See 3 more Smart Citations

The State of the Science in Patient-Reported Outcomes for Patients with Lung Cancer

Xiao

Hurst

Movsas

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

Patient-Reported Outcomes in Lung Cancer

Hurst

Siddiqui²,

Movsas³

2022

Medical Radiology

View full text Add to dashboard Cite

The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden

et al. 2019

View full text Add to dashboard Cite

Purpose Advanced non-small cell lung cancer (aNSCLC) impacts the lives of patients and their caregivers. This analysis examined the association between patient clinical characteristics and patient and caregiver humanistic burden. Methods Data for patients with aNSCLC and their informal caregivers in France, Germany and Italy, were collected between May 2015 and June 2016 via chart review and patient and caregiver surveys. Patients and caregivers completed validated instruments to evaluate their health state (EuroQol-5-dimensions-3-levels [EQ-5D-3L]), work and activity impairment (Work Productivity Activity Impairment [WPAI]) and health-related quality of life (HRQoL; European Organisation for Research and treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]). Caregivers also completed the Zarit Burden Interview (ZBI). Univariate and regression analyses were stratified by patient Eastern Cooperative Group Performance Status (ECOG-PS 0, 1, 2 or 3/4). Results In total, 1030 patients and 427 accompanying informal caregivers participated. Regression analyses indicated that patients reported lower EQ-5D-3L utility index, EQ-VAS and EORTC QLQ-C30 global health status and greater work and activity impairment with worsening ECOG-PS (all p < 0.05). Caregivers also reported greater activity impairment and higher ZBI scores with worsening ECOG-PS of the patient they were providing care for (all p < 0.05). Conclusions As patients’ functionality deteriorates as measured by the ECOG-PS, so do their outcomes related to health utility, work productivity, activity impairment and HRQoL. This deterioration is also reflected in increased caregiver burden and activity impairment. There is a need for interventions to maintain patients’ physical function to relieve the humanistic burden of both patients and caregivers. Electronic supplementary material The online version of this article (10.1007/s11136-019-02152-6) contains supplementary material, which is available to authorized users.

show abstract

Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?

Cited by 15 publications

References 52 publications

The State of the Science in Patient-Reported Outcomes for Patients with Lung Cancer

The State of the Science in Patient-Reported Outcomes for Patients with Lung Cancer

Patient-Reported Outcomes in Lung Cancer

The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden

Contact Info

Product

Resources

About